Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: How well do they predict clinical outcomes?

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 517-523

  Peters, Lars ^a   Rockstroh, Jürgen Kurt ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Fibrosis marker; FibroTest; hepatitis C; hyaluronic acid; MELD

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HYALURONIC ACID;

BLOOD ANALYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MIXED INFECTION; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM;

BIOLOGICAL MARKERS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 77958573055     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833e3ee6     Document Type: Review

References (32)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenter-ology 2008; 134:1670-1681.
3. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50:36-41.
4. Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12:1049-1061.
5. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-136.
6. Guechot J, Serfaty L, Bonnand AM, et al. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32:447-452.
7. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-1316.
8. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31:513-520.
9. Nahon P, Ganne-Carrie N, Degos F, et al. Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis. Gastroenterol Clin Biol 2005; 29:347-352.
10. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
11. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.
12. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
13. Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-1282.
14. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138:136-146.
15. Jalan R, Hayes PC. Review article: quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9:263-270.
16. Everson GT, Shiffman ML, Morgan TR, et al. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther 2008; 27:798-809.
17. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
18. Murillas J, Rimola A, Laguno M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009; 15:1133-1141.
19. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-1430.
20. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138:159-164.
21. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57.
22. Giron-Gonzalez JA, Brun F, Terron A, et al. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antivir Ther 2007; 12:899-907.
23. Tuma P, Jarrin I, Del Amo J, et al. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010; 24:745-753.
24. Fuster D, Clotet B. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother 2005; 6:1565-1572.
25. Guaraldi G, Cocchi S, Motta A, et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 2009; 37:250-255.
26. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCVFibroSure)and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8.
27. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52:1887-1896.
28. Leroy V. Other noninvasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32:52-57.
29. Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med 2005; 258:460-466.
30. Peters L, Mocroft A, Soriano V, et al. Hyaluronic acid as a prognostic marker of hepatic coma and liver-related death in HIV/viral hepatitis coinfected patients. Abstract 821,16th Conference on Retroviruses and Opportunistic Infections 2009. [Epub ahead of print]
31. Peters L, Neuhaus J, Mocroft A, et al. Interruption of ART and changes in hyaluronic acid as marker of liver fibrosis progression in strategies for management of ART viral hepatitis-co-infected participants and matched controls. Abstract 858, 16th Conference on Retroviruses and Opportunistic Infections 2009. [Epub ahead of print]
32. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-1353.